TY - STD TI - American Cancer Society: Cancer Facts & Figures 2013 [http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013] UR - http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/cancer-facts-figures-2013 ID - ref1 ER - TY - JOUR AU - Jemal, A. AU - Siegel, R. AU - Xu, J. AU - Ward, E. PY - 2010 DA - 2010// TI - Cancer statistics, 2010 JO - CA Cancer J Clin VL - 60 UR - https://doi.org/10.3322/caac.20073 DO - 10.3322/caac.20073 ID - Jemal2010 ER - TY - JOUR AU - Monzon, F. A. AU - Ogino, S. AU - Hammond, M. E. AU - Halling, K. C. AU - Bloom, K. J. AU - Nikiforova, M. N. PY - 2009 DA - 2009// TI - The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer JO - Arch Pathol Lab Med VL - 133 ID - Monzon2009 ER - TY - STD TI - Benson AB III: Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 2007,13 (6 Suppl C):S5–S18. ID - ref4 ER - TY - STD TI - Avastin [prescribing information]. South San Francisco, CA: Genentech, Inc; 2013. ID - ref5 ER - TY - STD TI - Erbitux [prescribing information]. Branchburg, NJ: ImClone LLC a wholly-owned subsidiary of Eli Lilly and Company, and Bristol-Myers Squibb Company; 2013. ID - ref6 ER - TY - STD TI - Vectibix [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2014. ID - ref7 ER - TY - JOUR AU - Soulières, D. AU - Greer, W. AU - Magliocco, A. M. AU - Huntsman, D. AU - Young, S. AU - Tsao, M. S. PY - 2010 DA - 2010// TI - KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies JO - Curr Oncol VL - 17 ID - Soulières2010 ER - TY - JOUR AU - Lièvre, A. AU - Artru, P. AU - Guiu, M. AU - Laurent-Puig, P. AU - Merlin, J. L. AU - Sabourin, J. C. PY - 2013 DA - 2013// TI - The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: a status report in France in 2011 JO - Eur J Cancer VL - 49 UR - https://doi.org/10.1016/j.ejca.2013.02.016 DO - 10.1016/j.ejca.2013.02.016 ID - Lièvre2013 ER - TY - JOUR AU - Tonini, G. AU - Imperatori, M. AU - Vincenzi, B. AU - Frezza, A. M. AU - Santini, D. PY - 2013 DA - 2013// TI - Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer JO - J Exp Clin Cancer Res VL - 32 UR - https://doi.org/10.1186/1756-9966-32-92 DO - 10.1186/1756-9966-32-92 ID - Tonini2013 ER - TY - JOUR AU - Xu, J. M. AU - Liu, X. J. AU - Ge, F. J. AU - Lin, L. AU - Wang, Y. AU - Sharma, M. R. PY - 2014 DA - 2014// TI - KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer JO - J Exp Clin Cancer Res VL - 33 UR - https://doi.org/10.1186/s13046-014-0104-7 DO - 10.1186/s13046-014-0104-7 ID - Xu2014 ER - TY - BOOK PY - 2008 DA - 2008// TI - Clinical practice guidelines in oncology (NCCN Guidelines), colon cancer PB - NCCN CY - Fort Washington ID - ref12 ER - TY - JOUR AU - Landsman-Blumberg, P. B. AU - Carter, G. G. AU - Johnson, B. H. AU - Sedgley, R. AU - Nicol, S. J. AU - Li, L. PY - 2014 DA - 2014// TI - Metastatic colorectal cancer treatment patterns according to kirsten rat sarcoma viral oncogene homolog genotype in U.S. Community-based oncology practices JO - Clin Colorectal Cancer VL - 13 UR - https://doi.org/10.1016/j.clcc.2014.05.001 DO - 10.1016/j.clcc.2014.05.001 ID - Landsman-Blumberg2014 ER - TY - BOOK PY - 2012 DA - 2012// TI - Clinical practice guidelines in oncology (NCCN Guidelines), colon cancer PB - NCCN CY - Fort Washington ID - ref14 ER - TY - JOUR AU - Tan, C. AU - Du, X. PY - 2012 DA - 2012// TI - KRAS mutation testing in metastatic colorectal cancer JO - Word J Gastroenterol VL - 18 ID - Tan2012 ER - TY - JOUR AU - Allegra, C. J. AU - Jessup, J. M. AU - Somerfield, M. R. AU - Hamilton, S. R. AU - Hammond, E. H. AU - Hayes, D. F. PY - 2009 DA - 2009// TI - American society of clinical oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2009.21.9170 DO - 10.1200/JCO.2009.21.9170 ID - Allegra2009 ER - TY - STD TI - Abrams TA, Meyer G, Schrag D, Meyerhardt JA, Moloney J, Fuchs CS: Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014, 106:djt371. ID - ref17 ER - TY - JOUR AU - Ciardiello, F. AU - Tejpar, S. AU - Normanno, N. AU - Mercadante, D. AU - Teague, T. AU - Wohlschlegel, B. PY - 2011 DA - 2011// TI - Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia JO - Target Oncol VL - 6 UR - https://doi.org/10.1007/s11523-011-0181-x DO - 10.1007/s11523-011-0181-x ID - Ciardiello2011 ER - TY - JOUR AU - Webster, J. AU - Kauffman, T. L. AU - Feigelson, H. S. AU - Pawloski, P. A. AU - Onitilo, A. A. AU - Potosky, A. L. PY - 2013 DA - 2013// TI - KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings JO - Cancer Epidemiol Biomarkers Prev VL - 22 UR - https://doi.org/10.1158/1055-9965.EPI-12-0545 DO - 10.1158/1055-9965.EPI-12-0545 ID - Webster2013 ER - TY - STD TI - Miller PJ, Walker MS, Landsman-Blumberg P, Cuyun Carter G: Using text mining of electronic medical records to identify KRAS testing status in mCRC patients [abstract]. Value Health 2013, 16:A21. ID - ref20 ER - TY - STD TI - Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmueller J, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, Scholz M, Mueller S, Schaefer B, Modest DP, Jung A, Stintzing S: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3) [abstract]. J Clin Oncol 2013, 31(18 suppl):Abstract LBA3506. ID - ref21 ER - TY - JOUR AU - Hess, G. P. AU - Wang, P. F. AU - Quach, D. AU - Barber, B. AU - Zhao, Z. PY - 2010 DA - 2010// TI - Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice JO - J Oncol Pract VL - 6 UR - https://doi.org/10.1200/JOP.2010.000072 DO - 10.1200/JOP.2010.000072 ID - Hess2010 ER - TY - JOUR AU - Kim, G. P. AU - Sargent, D. J. AU - Mahoney, M. R. AU - Rowland, K. M. AU - Philip, P. A. AU - Mitchell, E. PY - 2009 DA - 2009// TI - Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841 JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.4552 DO - 10.1200/JCO.2008.20.4552 ID - Kim2009 ER -